Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Overview - CarMax, Inc. is a retailer specializing in used cars, which has recently faced legal challenges due to allegations of misleading investors regarding demand for its vehicles [4]. Financial Performance - In the second quarter of fiscal year 2026, CarMax reported disappointing financial results, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [6]. - The company's net income for the second quarter was approximately $95.4 million, down from $132.8 million in the previous year [6]. Stock Performance - Following the announcement of disappointing financial results on September 25, 2025, CarMax's stock price dropped by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [7]. - An unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary outlook for Q3 2025, led to an additional stock price drop of over 24% [7]. Legal Proceedings - Investors have until January 2, 2026, to request to be appointed to lead the class action case, which is currently pending in the U.S. District Court for the District of Maryland [3]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in CarMax securities [3].

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Klarna Group plc (NYSE: KLAR) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Klarna securities pursuant to the registration statement and prospectus issu ...

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (NASDAQ: BYND) for potential violations of the federal securities laws. If you invested in Beyond Meat, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation. Why Is Beyond Meat Being Investigated for Securities Fraud?Beyond Meat makes plant-based meat alternatives. In late 2023, ...

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, with a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year [5]. - Following the announcement of these results, CarMax's stock dropped $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 2025 outlook, led to an additional stock drop of over 24% [6]. Group 3: Market Context - CarMax's previous claims of strong demand were allegedly inflated due to a temporary boost from U.S. tariffs on cars, which prompted customers to purchase vehicles before the tariffs took effect [3]. - The lawsuit also investigates whether CarMax properly assessed or reserved for its portfolio of car loans following the CEO's departure [4].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in CarMax securities [3]. - Investors have until January 2, 2026, to request to lead the case, which is currently pending in the U.S. District Court for the District of Maryland [3]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, with a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [6]. - The net income for the second quarter was approximately $95.4 million, down from $132.8 million in the previous year [6]. Group 3: Stock Price Impact - Following the announcement of poor financial results on September 25, 2025, CarMax's stock price fell by $11.45 per share, or about 20%, from $57.05 to $45.60 [7]. - The unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 2025 outlook, led to an additional drop of over 24% in the stock price [7]. Group 4: Company Operations - CarMax's management had previously emphasized strong demand for its vehicles, which was allegedly inflated by a temporary surge in purchases before U.S. tariffs were imposed [4]. - The law firm BFA is also investigating whether CarMax adequately assessed or reserved for its portfolio of car loans following the CEO's departure [5].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year, attributed to a "pull forward" in demand due to U.S. tariffs [5]. - Following the financial report, CarMax's stock dropped $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 2025 outlook led to an additional stock drop of over 24% [6]. Group 3: Company Background - CarMax is a leading retailer of used cars, emphasizing strong and sustainable demand driven by a seamless customer experience [3]. - The law firm Bleichmar Fonti & Auld LLP, known for representing plaintiffs in securities class actions, is handling the lawsuit against CarMax [10].

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price attributed to misleading statements regarding demand and financial performance [2][4]. Group 1: Lawsuit Details - A class action lawsuit has been filed against CarMax and its senior executives for securities fraud, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [4]. - The lawsuit alleges that CarMax misled investors about the sustainability of demand for its vehicles, particularly in light of U.S. tariffs on cars [5]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [7]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [7]. - The decline in sales was attributed to a "pull forward" in demand due to the announcement of tariffs, which led to a temporary increase in purchases before the tariffs took effect [7]. Group 3: Stock Price Reaction - Following the disappointing financial results announced on September 25, 2025, CarMax's stock price dropped by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [8]. - An additional drop of over 24% occurred after the unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary outlook for Q3 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant drop in stock price due to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Reasons for the Lawsuit - CarMax has been accused of misleading investors about the demand for its used cars, which was allegedly inflated by short-term factors such as U.S. tariffs [3]. - The company reported disappointing financial results for Q2 FY 2026, including a 5.4% decline in retail used unit sales and a net income drop from $132.8 million to $95.4 million year-over-year [5]. Group 3: Stock Performance - Following the announcement of poor financial results on September 25, 2025, CarMax's stock price fell by $11.45, or approximately 20%, from $57.05 to $45.60 per share [6]. - The unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 2025 outlook, led to an additional stock drop of over 24% [6].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [1][3]. Financial Performance and Stock Movement - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to certain long-lived assets, which was anticipated to be material. This announcement led to a significant stock price drop of approximately 23%, from $2.84 per share on October 23, 2025, to $2.185 per share on October 24, 2025 [4]. - Following the impairment announcement, the company delayed its earnings announcement for Q3 2025 on November 3, 2025, due to the need for additional time to complete the impairment review, resulting in further declines in stock price during trading on that day [5]. Company Operations and Asset Management - In late 2023, Beyond Meat conducted a global operations review and depreciated certain long-lived assets, stating that these assets were recorded at the lower of their carrying value or fair value less costs to sell, with no impairments reported [2].

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which affected investors between December 27, 2023, and May 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the expected timeline for FDA approval of aficamten, indicating approval in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - It is alleged that the company failed to disclose significant risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA about safety monitoring and risk mitigation but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Investor Information - Investors who suffered losses in Cytokinetics during the specified timeframe have until November 17, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].